Journal: Arthritis Research & Therapy

Article Title: Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS

doi: 10.1186/s13075-015-0675-5

Figure Lengend Snippet: Reduced Sox9 expression but increased COL2 expression in ankylosing spondylitis facet joints. Percentage of positively stained chondrocytes among all chondrocytes [%] and representative immunohistochemical staining of Sox9 ( a ) and COL2 ( b ) within the hyaline articular cartilage of facet joints from controls (CO; A–B upper pictures ), patients with ankylosing spondylitis (AS; A–B middle pictures ) and osteoarthritis (OA; A–B lower pictures ); original magnification 40× and 400×; ns = not significant p >0.05; ***= p <0.001; *= p <0.05. COL2 type II collagen, Sox9 sex determining region Y (SRY)-box 9

Article Snippet: Monoclonal mouse antibodies against osteocalcin (clone 190125, dilution 1:100; R&D Systems, Minneapolis, MN, USA), wif-1 (clone 133015, dilution 1:30; R&D Systems, Minneapolis, MN, USA), COL2 (clone II-4C11, dilution 1:75; Acris Antibodies GmbH, Herford, Germany), COL10 (clone X53, dilution 1:25; Quartett, Berlin, Germany), polyclonal rabbit antibodies against beta-catenin (dilution 1:50; Thermo Fisher Scientific, Waltham, MA, USA), DKK-1 (dilution 1:50; Abcam, Cambridge, UK), sclerostin (dilution 1:100; Abcam, Cambridge, UK), Runx2 (dilution 1:40; Quartett, Berlin, Germany), BMP-2 and BMP-7 (dilution 1:20; PeproTech, Rocky Hill, NJ, USA) and polyclonal goat antibodies against MMP13 (dilution 1:20) and Sox9 (dilution 1:20) both obtained from R&D Systems (Minneapolis, MN, USA) were used.

Techniques: Expressing, Staining, Immunohistochemical staining

Journal: Arthritis Research & Therapy

Article Title: Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model

doi: 10.1186/s13075-016-0931-3

Figure Lengend Snippet: Inflammation in delayed-type hypersensitivity arthritis (DTHA) is accompanied by early cartilage damage and bone resorption that precedes new bone formation. a Representative examples of Safranin O/Fast Green and collagen type X (COLX)- and osteocalcin (OC)-stained tissue sections of DTHA or control [phosphate-buffered saline (PBS)] paws at indicated time points. c cartilage, b bone, i inflammation, bm bone marrow, nc new cartilage, nb new bone. Safranin O/Fast Green original magnification × 100, COLX and OC original magnification × 200. b Histological scores of cartilage damage and bone resorption performed on Safranin O/Fast Green–stained tissue sections and of new bone formation performed on COLX- and OC-stained sections ( n = 10 per time point). c Assessment of endochondral or direct bone formation or both types in tissue sections of methylated bovine serum albumin (mBSA)-challenged paws at indicated time points assessed on COLX- and OC-stained tissue sections.

Article Snippet: After blocking of nonspecific binding by goat serum (10 %; Dianova, Hamburg, Germany) for 15 minutes, sections were incubated with anti-osteocalcin (polyclonal rabbit, dilution 1:500; Enzo Life Sciences AG, Lausen, Switzerland) and anti-COLX (clone X53, dilution 1:25; Quartett Immunodiagnostics, Berlin, Germany) overnight at 4 °C.

Techniques: Staining, Methylation

Journal: Arthritis Research & Therapy

Article Title: Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model

doi: 10.1186/s13075-016-0931-3

Figure Lengend Snippet: Treatment with monoclonal antibody (mAb) against receptor activator of nuclear factor κB ligand (anti-RANKL) prevents erosive joint damage in delayed-type hypersensitivity arthritis (DTHA) but has no effect on new bone formation. Mice were treated with 500 μg of anti-RANKL mAb or isotype control in 200 μl of phosphate-buffered saline three times weekly from the time of immunization (day −7). a Histopathological scoring of inflammation, periarticular and subchondral pannus formation, cartilage damage, bone resorption, and bone formation on day 11 after arthritis induction in paws from DTHA mice treated with either anti-RANKL or isotype control (mean ± standard error of the mean, n = 10). *** p < 0.001 (Student’s t test). b Representative immunohistochemical osteocalcin staining of arthritis paws on day 11 after arthritis induction in anti-RANKL- and isotype control–treated mice ( left panel original magnification × 40, right panel original magnification × 400). b bone, c cartilage, gt granulation tissue, i inflammation, nb new bone

Article Snippet: After blocking of nonspecific binding by goat serum (10 %; Dianova, Hamburg, Germany) for 15 minutes, sections were incubated with anti-osteocalcin (polyclonal rabbit, dilution 1:500; Enzo Life Sciences AG, Lausen, Switzerland) and anti-COLX (clone X53, dilution 1:25; Quartett Immunodiagnostics, Berlin, Germany) overnight at 4 °C.

Techniques: Immunohistochemical staining, Staining